We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ERS Genomics Logo

ERS Genomics

ERS Genomics was formed to commercialize the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. The team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development.

Latest ERS Genomics Content

Double helix structure of DNA.
Product News

ERS Genomics and Université De Montréal Sign CRISPR/Cas9 License Agreement

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services.
Double helix structure of DNA.
Product News

ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications.
Double helix structure of DNA.
Product News

ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering.
Double helix structure of DNA.
Product News

Ers Genomics and StemSight Sign CRISPR/Cas9 License Agreement

License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.
Double helix structure of DNA.
Product News

Key Charpentier/Doudna CRISPR Patent Upheld by Japanese Patent Office

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced its second Japanese Patent.
How CRISPR Is Transforming High-Throughput Screening content piece image
Industry Insight

How CRISPR Is Transforming High-Throughput Screening

This article walks through the fundamentals of CRISPR screening and its most exciting applications, including unpicking cellular signaling networks, discovering how viruses like COVID-19 infect our cells and finding new drug targets.
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement content piece image
Product News

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.
What’s Hot in Synthetic Biology Right Now? content piece image
Industry Insight

What’s Hot in Synthetic Biology Right Now?

In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.
New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge  content piece image
Product News

New CRISPR/Cas9 License Agreement for ERS Genomics and Cytosurge

ERS Genomics Limited has announced a new license agreement with Cytosurge AG. This is a non-exclusive licensing agreement granting Cytosurge access to the ERS CRISPR/Cas9 patent portfolio.
Researcher in PPE reaching towards a strand of DNA.
Article

Cas9 or Cas12? Picking the Right CRISPR System for Your Research

What are the major differences between Cas9 and Cas12, and how can you decide which is right for your research?
Advertisement